At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U. S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U. S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
8
Total Investments
8
Portfolio Companies
-
Exits
1
Industries
General Information
Industries
Pharmaceutical
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Eisai
Recent Investments (8)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series A | •••••• | Aug 2024 | |
| Corporate Round | •••••• | Mar 2024 | |
| Series C | •••••• | Nov 2022 | |
| Post-IPO Equity | •••••• | Aug 2022 | |
| Series A | •••••• | Jan 2022 | |
|
|
Series C | •••••• | Oct 2021 |
|
|
Series A | •••••• | Apr 2021 |
|
|
Series A | •••••• | Nov 2020 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.